Nanoviricides Incorporated (NYSEMKT:NNVC)’s Stock Is Sell After More Market Selling

July 18, 2017 - By Hazel Jackson

 Nanoviricides Incorporated (NYSEMKT:NNVC)'s Stock Is Sell After More Market Selling

Investors sentiment increased to 1.33 in Q4 2016. Its up 0.69, from 0.64 in 2016Q3. It increased, as 1 investors sold NanoViricides Inc shares while 8 reduced holdings. 5 funds opened positions while 7 raised stakes. 3.43 million shares or 7.33% more from 3.20 million shares in 2016Q3 were reported.
Quantitative Systematic Strategies Limited Liability Com has 10,000 shares. Hightower Advsrs Ltd Liability Co invested in 13,429 shares. Sequoia Advsr Ltd Liability Company has 17,583 shares for 0% of their portfolio. Bankshares Of New York Mellon stated it has 0% in NanoViricides Inc (NYSEMKT:NNVC). Fayez Sarofim & invested 0% of its portfolio in NanoViricides Inc (NYSEMKT:NNVC). State Street reported 0% in NanoViricides Inc (NYSEMKT:NNVC). Renaissance Technology Limited Liability Company holds 0% in NanoViricides Inc (NYSEMKT:NNVC) or 370,600 shares. Raymond James & Assoc holds 62,000 shares. Cowen Grp Inc holds 0% of its portfolio in NanoViricides Inc (NYSEMKT:NNVC) for 373,750 shares. Blackrock Investment Mngmt Lc stated it has 7,253 shares. Creative Planning has 16,513 shares for 0% of their portfolio. Pioneer Trust Natl Bank N A Or has 0.03% invested in NanoViricides Inc (NYSEMKT:NNVC) for 53,572 shares. Tower Rech Cap Llc (Trc) owns 18,704 shares or 0% of their US portfolio. Royal Commercial Bank Of Canada has 700 shares for 0% of their portfolio. Wharton Business Grp Inc Limited Liability has invested 0.05% in NanoViricides Inc (NYSEMKT:NNVC).

The stock of Nanoviricides Incorporated (NYSEMKT:NNVC) registered an increase of 13.14% in short interest. NNVC’s total short interest was 1.80 million shares in July as published by FINRA. Its up 13.14% from 1.60 million shares, reported previously. With 139,900 shares average volume, it will take short sellers 13 days to cover their NNVC’s short positions.

The stock increased 1.44% or $0.02 on July 17, reaching $1.41. About shares traded. NanoViricides Inc (NYSEMKT:NNVC) has declined 13.42% since July 18, 2016 and is downtrending. It has underperformed by 30.12% the S&P500.

NanoViricides, Inc. is a nano-biopharmaceutical company. The company has market cap of $90.21 million. The Firm is a development-stage firm with several drugs in various stages of development. It currently has negative earnings. The Firm focuses on its research and clinical programs on specific anti-viral therapeutics.

More notable recent NanoViricides Inc (NYSEMKT:NNVC) news were published by: Prnewswire.com which released: “NanoViricides Reports Its Drug Candidates Significantly Reduced the Extent of …” on July 10, 2017, also Prnewswire.com with their article: “NanoViricides CEO to Present Information on Its Topical Shingles Treatment At …” published on June 13, 2017, Seekingalpha.com published: “NanoViricides: House Of Cards With -80% Downside, ‘Strong Sell’ Recommendation” on February 11, 2014. More interesting news about NanoViricides Inc (NYSEMKT:NNVC) were released by: Nasdaq.com and their article: “Pioneer Trust Bank NA Buys Altria Group Inc, Automatic Data Processing Inc …” published on July 08, 2017 as well as Prnewswire.com‘s news article titled: “NanoViricides Abstract Accepted for Poster Presentation at the 2017 Annual …” with publication date: June 20, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.